Mark K. Oki's most recent trade in Achieve Life Sciences Inc. was a trade of 168,000 Common Stock done . Disclosure was reported to the exchange on Sept. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2025 | 168,000 | 178,000 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | 18 Sep 2025 | 168,000 | 0 | - | - | Performance Restricted Stock Unit (PRSU) | ||
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.92 per share. | 18 Sep 2025 | 50,060 | 127,940 (0%) | 0% | 2.9 | 146,175 | Common Stock |
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | 04 Sep 2025 | 168,000 | 0 | - | - | Performance Restricted Stock Unit | ||
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.89 per share. | 17 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 2.9 | 28,887 | Common Stock |
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | 28 Jan 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | ||
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | 06 Dec 2024 | 168,000 | 168,000 | - | - | Performance Restricted Stock Unit (PRSU) | ||
| Achieve Life Sciences Inc | Mr. Mark K. Oki | Chief Financial Officer | 06 Dec 2024 | 72,000 | 72,000 | - | - | Common Stock Options (right to buy) | ||
| Aytu BioPharma Inc | Mr. Mark K. Oki | Chief Financial Officer | 11 Aug 2023 | 13,000 | 13,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Aytu BioPharma Inc | Mr. Mark K. Oki | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.23 per share. | 18 Nov 2022 | 90,000 | 190,000 (0%) | 0% | 0.2 | 20,700 | Common Shares |
| Aytu BioPharma Inc | Mr. Mark K. Oki | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.23 per share. | 18 Nov 2022 | 90,000 | 190,000 (0%) | 0% | 0.2 | 20,700 | - |
| Aytu BioPharma Inc | Mr. Mark K. Oki | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2022 | 100,000 | 100,000 (0%) | 0% | 0 | Common Shares |